FDA Launches TEMPO Pilot Program for Post-Market Digital Health Surveillance
The U.S. Food and Drug Administration (FDA) launched the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program to evaluate how digital health technologies can collect real-world performance data. This initiative transitions the agency toward a more agile, post-market surveillance model that uses patient-reported outcomes to inform regulatory decisions for software as a medical device (SaMD).
Telemetry is advisory — directional context, not a deterministic risk score.
Strategic Governance Impact
Structural governance significance — not general importance.
Governance shift
The FDA has launched the TEMPO pilot program, transitioning Software as a Medical Device regulation from one-time pre-market approvals to continuous post-market surveillance. This initiative shifts evidence and compliance expectations from static, point-in-time submissions to continuous real-world performance monitoring. This change redefines how digital health organizations establish product safety, requiring active, continuous assurance frameworks rather than retrospective testing.
Exposure pathway
Manufacturers of digital health devices and SaMD are exposed to shifting clinical evidence requirements, moving from static pre-market submissions to continuous real-world evidence (RWE) monitoring. Regulatory affairs and clinical outcome assessment teams must prepare for integrated, high-frequency data collection workflows.
What may need to be proven
Companies will be expected to provide evidence of validated patient-centered outcome measures (PCOMs) and demonstrate the technical capability to transmit secure, high-integrity performance data directly from the device to regulatory systems.
Operational consequence mapping
What this signal actually changes
- What operational condition changed?
- The FDA is shifting from one-time clinical trial data to continuous, technology-enabled monitoring of device efficacy in the post-market phase.
Consequence analysis · premium
Full operational consequence mapping — actors exposed, broken assumptions, evidence expectations, operational burden — is reserved for Premium and Executive subscribers.
Request accessSource citation
US FDA
GRandCIndex monitors source publications without reproducing them verbatim. Original materials remain the authoritative reference.
Executive interpretation · premium
Premium subscribers receive structured interpretation: cross-jurisdictional read-across, board-level translation, and proof-exposure mapping linked to internal control taxonomy.
Request accessConvergent signals
Reinforcing pressure across different stories
- Emerging2026-08-18US#fda#generative-ai#samd#medical-device-regulationSIG-2026-JMPK1QStrongEscalatingMid-termEngineering
US FDA Issues Discussion Paper on Generative AI-Enabled Medical Device Oversight
The U.S. Food and Drug Administration (FDA) published a discussion paper exploring regulatory frameworks for generative artificial intelligence (GenAI) in medical devices, marking the agency's formal move toward defining specific safety and effectiveness standards for non-deterministic AI. The paper seeks industry input on high-risk use cases, premarket evidentiary requirements, and the management of 'hallucinations' or output errors in clinical settings. This initiative signals a shift from general Software as a Medical Device (SaMD) policies toward a specialized, risk-based approach for foundation models and large language models (LLMs) used in healthcare.
Pattern context
Related signals in the same risk surface
- High2026-08-25US#ics-security#transportation-safety#vulnerability-management#cisa-advisorySIG-2026-U8RTT9StrongEscalatingImmediateEngineering
CISA Issues Critical Advisory on Bendix EC80 Brake ECU Vulnerabilities Impacting Transportation Systems
The Cybersecurity and Infrastructure Security Agency (CISA) released an Industrial Control Systems (ICS) advisory detailing high-severity vulnerabilities in Bendix EC80 Brake Electronic Control Units (ECUs). These flaws, including stack-based buffer overflows and hard-coded credentials, could allow attackers to remotely execute code or inject CAN bus traffic, potentially disabling critical vehicle functions such as ABS, steering assist, and traction control. This advisory highlights structural risks to fleet operations and transportation safety across North America.
+3 more related signals · premium